Targeted nanoparticles to inhibit a key factor in bone metastatic tumors
Official title: Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors
Funded at Vanderbilt University Medical Center · NIH-11092116 · Data updated 2026-11-12
This study is testing a new way to deliver a special treatment called GANT58 directly to bone tumors caused by cancers like breast, prostate, and lung cancer, using tiny particles that help the medicine work better and target the right areas to help reduce pain and improve your health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $648,024 |
| NIH project number | 5R01CA264508-03 |
| Project ID | NIH-11092116 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with bone metastatic tumors originating from breast, prostate, or lung cancers.
✕Less likely to help
Patients without bone metastases or those with primary tumors not involving the bone may not benefit from this research.
What this research studies
This research focuses on developing advanced nanoparticles designed to deliver a specific inhibitor, GANT58, to bone metastatic tumors. These tumors often arise from cancers such as breast, prostate, and lung cancer, leading to severe complications like pain and fractures. The study aims to enhance the bioavailability and effectiveness of GANT58 by using polymeric nanoparticles that respond to reactive oxygen species, ensuring targeted delivery to the affected bone areas. By improving the pharmacokinetics of the treatment, the research seeks to reduce tumor-induced bone disease and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that significantly alleviates pain and complications associated with bone metastases.
How similar studies have gone: Previous research has shown promise in using targeted nanoparticles for drug delivery in cancer treatment, indicating a potential for success in this novel approach.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Rhoades (Sterling), Julie a — Vanderbilt University Medical Center
- Study coordinator: Rhoades (Sterling), Julie a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.